This episode of The Nordic Venture Show podcast features Desentum, a clinical-stage biopharmaceutical company focused on developing novel allergen immunotherapy (AIT) products. The company aims to re-educate the immune system to switch from hypersensitivity to tolerance through modified hypoallergens, providing a safer and more effective treatment than traditional methods. Desentum's technology involves targeted modifications to allergens and controlled release formulations to reduce adverse reactions while inducing a protective immune response.